Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Englumafusp Alfa in Combination With Obinutuzumab and Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT04077723Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2019
- Primary completion
- Mar 2027
- Modality
- Bispecific Antibodies, Fc Fusion Proteins, Fc-Fusion Proteins
- Countries
- 12
01
Overview
A Phase 2 trial of englumafusp alfa in non-Hodgkin lymphoma (NHL), sponsored by Roche. Started Aug 2019; status: active, not recruiting.
02
Drugs
englumafusp alfa
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04077723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077723.